Natl Center for health statistics 11/24 report shows in 2023, 24% of adults had chronic pain (8.5% that limited life/work=high-impact chronic pain). Chronic pain and high-impact chronic pain both increased with age & decreasing urbanization. https://t.co/tMmgHVWnCf https://t.co/O3P4Vrmkei

Rheumatic findings in sarcoidosis are found in 10–40% of pts and include bone lesions, acute arthritis, chronic arthritis, axial disease, dactylitis, and sarcoid myopathy, https://t.co/WsfmKUS2n5 https://t.co/3j8OHgw7AS

Nailfold video-capillaroscopy (NVC) study of 76 dermatomyositis (DM) pts - 74% had anomalous NVC patterns (diminished density, abnl morphology). NVC abnl pts had more Raynaud's, and cluster 1 were more likely to develop ILD.https://t.co/OC7jNHdFMn https://t.co/cCCO70Xzoh

ICYMI: Sex related differences in PsA Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and… https://t.co/60vdbWLltB https://t.co/nY1CuJhKMb

41 "Rhupus" pts were compared to 160 SLE and 709 RA pts. Rhupus pts have a younger onset age than RA (P=0.032), but older than SLE (P=0.008). ~20% initially presented w/ SLE Sxs. Rhupus commonly has ILD, hyperglobulinemia & Lab abnormalities (61%), but seldom renal or CNS dz… https://t.co/pqfmFGT0D6 https://t.co/zo0APuAcQS

3 biosimilars from Celltrion have received a positive recommendatoin from the CHMP of the EMA for pt), Stoboclo and Osenvelt (denosumab biosimilars), and Avtozma (tocilizumab biosimilar), possibly redefining treatment affordability and accessibility across Europe.… https://t.co/dYXfUSpP5I https://t.co/wLQMXomoVS

U.S. Preventive Services Task Force (USPSTF) has recommended AGAINST use of vitamin D +/- Ca for the primary prevention of fractures (or falls) in postmenopausal women/men > 60 years of age. or older.https://t.co/1bUBqTVaX0 https://t.co/AXWxduVkOT

RheumNow Live 2025: Feb 8-9, Dallas, TX! 🔬 Don’t miss top experts on Psoriatic Disease: ➡️ A. Ogdie: Preventing PsA ➡️ A. Kavanaugh: Biologic Therapies ➡️ K. Gordon: Head-to-Head Studies Register now! https://t.co/BTLmc8HSKY https://t.co/KVsLF3yOZx

ICYMI: Beyond the Needle: Redefining the Assessment of Lupus Nephritis Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE). When not captured early, patients are at high risk of progressing to end-stage renal disease, which… https://t.co/ctngE0bMkX https://t.co/koDBZaPc19

ICYMI: Are Emulation Trials a Fantasy? https://t.co/eCO8a1UFlB https://t.co/PPczmxYFKa

54K Peptic Ulcers Annually (12.13.2024) Dr. Jack Cush reviews the news and journal reports from the past week on https://t.co/V10S4oVFsv https://t.co/rHw1qgxzIP https://t.co/cOdGQ5cAPD

Efficacy and Safety of Nipocalimab for Sjogren's Syndrome Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled,… https://t.co/kkIOCUZRml https://t.co/nL47c5veCp